Clinical Trial Update: Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial [Phase 2]

View source ↗

Summary

A randomized Phase II trial compares sorafenib plus doxorubicin versus sorafenib alone in advanced hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Adriamycin (doxorubicin)
• Sorafenib (Sorafenib)

Snippet

Sponsor: PD Dr. med. Matthias Dollinger | Conditions: Liver Carcinoma | Phase 2 | Status: UNKNOWN